Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Zevra Therapeutics Inc

ZVRA ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$12.68

▲ +2.22%

Market Cap $752.69M · Vol 320.64K

Key Metrics

P/E Ratio

13.23

FWD: 13.14

Market Cap

$752.69M

Small Cap

Div Yield

N/A

EPS Growth

-20.99%

YoY

RSI (14)

65.72

Momentum

Beta

0.97

vs Market

52W High

$15.03

15.67% below

52W Low

$7.16

77.03% above

Volume

320.64K

Avg 353.72K

P/B

3.29

Price-to-book

ROE

85.66%

Return on equity

Free Float

98.60%

Public shares

Shariah Compliance8 STANDARDS

✗ Zevra Therapeutics Inc (ZVRA) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ZVRA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+7.96%

+9.65%

+4.84%

+41.15%

YTD

+41.46%

+52.16%

+140.97%

+41.46%

Financials & Valuation

TTM · Annual

Total Revenue	$106.47M
Net Income	$83.23M
Revenue Growth (YoY)	+53.25%
Gross Margin	80.89%
Operating Margin	-3.98%
Net Profit Margin	78.17%
ROE	85.66%
ROA · ROIC	37.45% · 57.57%

P/E Ratio	13.23
Forward P/E (FY1)	13.14
PEG Ratio	0.04
P/S	4.82
P/B	3.29
P/FCF	N/A
EPS Growth	-20.99%
Outstanding Shares	59.38M

Technical Indicators

50-Day SMA	$12.02
200-Day SMA	$10.30
RSI (14)	65.72
Beta	0.97
52-Week High	$15.03
52-Week Low	$7.16

Volume Today	320.64K
Avg Daily Volume (30D)	353.72K
Relative Volume	0.91x
Volatility (10D)	31.65
Volatility (30D)	47.89
Free Float	98.60%

Analyst Consensus

BUY

Current Price $12.68

Mean Target $25.25

52W Low$7.16 52W High$15.03

Current

Target

$7.16 $15.03

Current Analyst target

+99.21% upside potential · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG0026ZG1G4

ISINUS4884452065

CountryUnited States of America

Sub-IndustryProprietary & Advanced Pharmaceuticals

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

MRK Merck & Co Inc -1.24% MRK.DE Merck KGaA -0.37% HALO Halozyme Therapeutics Inc -1.71% 4151.T Kyowa Kirin Co Ltd -1.09% 326030.KS SK Biopharmaceuticals Co Ltd +0.23%

Company Profile

Zevra Therapeutics, Inc. is a commercial-stage rare disease company with a late-stage pipeline committed to bringing therapeutics to people living with rare diseases. Its commercial products and active development assets are MIPLYFFA, Arimoclomol, OLPRUVA, and Celiprolol. Its lead product, Niemann-Pick disease type C (NPC), is a rare, progressive neurodegenerative disorder. NPC is an ultra-rare and progressive neurodegenerative disease characterized by an inability of the body to transport cholesterol and lipids inside of cells. OLPRUVA (sodium phenylbutyrate) for oral suspension is approved in the United States as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of UCDs involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase. Celiprolol is a selective adrenoceptor modulator (SAM). Celiprolol is approved in certain EU states for the treatment of hypertension and angina.